Bris­tol My­ers wants to pull out of its Abrax­ane deal in Chi­na. BeiGene says no way

A year and a half af­ter Chi­nese of­fi­cials or­dered BeiGene to stop sell­ing Bris­tol My­ers Squibb’s Abrax­ane in the wake of an alarm­ing in­spec­tion of a US fa­cil­i­ty, the man­u­fac­tur­ing is­sues at the root of the im­port sus­pen­sion still ap­pear un­re­solved.

And Bris­tol My­ers wants to axe the Abrax­ane sup­ply deal al­to­geth­er.

But BeiGene, which is cur­rent­ly in ar­bi­tra­tion pro­ceed­ings against its Big Phar­ma part­ner, won’t let it off the hook so eas­i­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER